<p>•MacroGenics 将在交易完成后从 Bora 获得 1.225 亿美元的预付款</p>
<p>•交易包括将制造基地、合同开发与制造（CDMO）业务及相关人员转移至 Bora</p>
<p>马里兰州洛克维尔，2026 年 5 月 11 日（全球新闻通讯社）——MacroGenics, Inc.（纳斯达克：MGNX），一家专注于开发创新抗体治疗癌症的临床阶段生物制药公司，以及 Bora Pharmaceuticals Co., Ltd.（台湾证券交易所：6472；OTCQX：BORAY），一家全球领先的制药制造公司，今天宣布他们已达成一项最终协议，MacroGenics 将把其良好生产规范（GMP）药物原料生产业务出售给 Bora，交易需满足常规的成交条件。</p>
<p>“当 MacroGenics 在去年阐明其战略优先事项时，我们承诺建立一个更专注的公司，致力于推进我们的创新管线并为股东创造长期价值。这笔交易通过提供额外的非稀释资本来加速我们的管线，支持我们在 2026 年及以后的关键价值转折点，这与我们的战略相符，” MacroGenics 的总裁兼首席执行官 Eric Risser 表示。“这笔交易还将使合同开发与制造组织（CDMO）业务在 Bora 的所有权下扩展，同时使 MacroGenics 能够继续获得扩展的开发和制造能力，以支持我们当前和未来的管线。”</p>
<p>“我们很高兴将这个高质量的马里兰制造基地及其优秀的员工整合到我们集团的全球 CDMO 努力中，” Bora 集团董事长 Bobby Sheng 表示。“我们将这次收购视为我们战略的重要组成部分，旨在扩大 Bora 在北美的生物制药业务，隶属于 Bora Biologics。结合我们在巴尔的摩的药物产品业务，我们的目标是将 Bora 建立为生物药物原料和药物产品的临床及商业生产的首选合作伙伴。”</p>
<p>根据资产购买协议的条款，Bora 将向 MacroGenics 支付 1.225 亿美元的预付款，交易费用和支出除外。交易完成后，Bora 将承担支持临床和商业生产的 MacroGenics 制造业务的责任。位于马里兰州洛克维尔的总部，包括 FDA 批准的总容量为 11,000 升的设施，以及马里兰州弗雷德里克的仓库将转移给 Bora。此外，预计约 140 名 MacroGenics 员工将被 Bora 聘用。两家公司将共同努力确保无缝过渡，并继续为 MacroGenics 及任何现有 CDMO 客户提供服务。作为交易的一部分，MacroGenics 将与 Bora 达成供应协议，以支持其内部管线需求的工艺开发和药物原料生产。交易预计将在 2026 年第三季度完成，需满足或放弃常规成交条件。</p>
<p>Moelis &amp; Company LLC 担任本次交易的独家财务顾问，Sidley Austin LLP 担任 MacroGenics 的法律顾问。</p>
<p>Jones Day 担任 Bora 在本次交易中的法律顾问。</p>
<p><strong>关于 MacroGenics, Inc.</strong></p>
<p>MacroGenics 是一家专注于开发创新单克隆抗体治疗癌症的生物制药公司。MacroGenics 的产品候选管线主要来自其专有的下一代抗体技术平台，这些平台在广泛的治疗领域中具有适用性。MacroGenics 的技术平台与蛋白质工程专业知识的结合，使公司能够生成有前景的产品候选者，并与全球制药和生物技术公司建立多项战略合作关系。有关更多信息，请访问 MacroGenics 的网站 www.macrogenics.com。MacroGenics 及其标志为 MacroGenics, Inc.的商标或注册商标。</p>
<p><strong>关于 Bora Pharmaceuticals</strong></p>
<p>Bora Pharmaceuticals（“Bora” 或 “公司”，6472.TW 和 BORAY.OTCQX）成立于 2007 年，是一家领先的制药服务公司，愿景和目标是 “为全球更好的健康做贡献”。Bora 采用 “双引擎” 模式，整合 CDMO 和商业专业知识，帮助制药和生物技术合作伙伴优化产品开发，加速上市，并扩大供应以满足全球患者需求。同时，Bora 积极拓展研发和销售基础设施，专注于小众和罕见疾病市场，以改善患者的生活质量。</p>
<p>通过投资人才、基础设施和生物制药扩展，Bora 持续转型运营，实现可持续增长。Bora 致力于使成功 “确定”，在制药和 CDMO 行业树立新标准。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿中关于 MacroGenics（“公司”）未来预期、计划和前景的任何声明，包括关于公司战略、未来运营、公司治疗候选药物的临床开发和监管计划、临床更新和公司正在进行的临床试验的安全性和有效性数据发布的预期时间，以及包含 “受制于”、“相信”、“预期”、“计划”、“期待”、“打算”、“估计”、“潜在”、“项目”、“可能”、“将”、“应该”、“会”、“能够”、“可以” 等词语的其他声明，或通过战略讨论，包括我们在 2025 年和 2026 年执行关键战略优先事项的能力，构成根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括：TZIELD、lorigerlimab、ZYNYZ 或任何其他产品候选药物的收入、费用和成本可能未如预期，TZIELD、lorigerlimab、ZYNYZ 或任何其他产品候选药物的市场接受度、竞争、报销和监管行动的风险；未来数据更新，包括关于正在进行的临床试验中产品候选药物的有效性和安全性数据的时间和结果；我们为客户提供制造服务的能力；未来临床试验的启动和招募中固有的不确定性；为资助我们产品候选药物的内部开发而获得融资的可用性；扩展正在进行的临床试验的预期；监管审查过程中的时间和步骤要求的预期；监管批准的预期；未来里程碑付款的预期；竞争产品的影响；我们与战略合作伙伴达成协议的能力以及可能影响公司产品候选药物的可用性或商业潜力的其他事项；由于灾难或其他事件（包括自然灾害、恐怖袭击、内乱和实际或威胁的武装冲突，或公共卫生危机）导致的商业、经济或政治中断；诉讼费用和未能成功辩护诉讼及其他对我们的索赔；以及公司在向证券交易委员会提交的文件中描述的其他风险。此外，本新闻稿中包含的前瞻性声明仅代表公司截至本日期的观点。公司预计后续事件和发展将导致公司观点的变化。然而，尽管公司可能选择在未来某个时点更新这些前瞻性声明，但公司特别声明不承担这样做的任何义务，除非法律要求。这些前瞻性声明不应被视为代表公司在本日期之后的任何日期的观点。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE56ZzFNeU0zTlRrMk9UYzFJekl3TURnNU5UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE56ZzFNeU0zTlRrMk9UYzFJekl3TURnNU5UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjhjYmJkN2ItMDIzNC00N2FjLThlYmMtMTQ0NjE2ZjA0OTc4LTEwMjA1MzAtMjAyNi0wNS0xMS1lbg==/tiny/MacroGenics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjhjYmJkN2ItMDIzNC00N2FjLThlYmMtMTQ0NjE2ZjA0OTc4LTEwMjA1MzAtMjAyNi0wNS0xMS1lbg==/tiny/MacroGenics-Inc-.png"/></p>
<pre><code>MacroGenics:Jim Karrels, 高级副总裁，首席财务官 1-301-251-5172info@macrogenics.comArgot Partners1-212-600-1902macrogenics@argotpartners.com
</code></pre>

MGNX

<p>MacroGenics, Inc. 已与 Bora Pharmaceuticals 达成协议，以 1.225 亿美元出售其 GMP 制造业务。该交易包括制造地点及相关人员的转移，预计将在 2026 年第三季度完成。这一举措与 MacroGenics 专注于其创新产品线并提供非稀释资本的战略相一致。Bora 旨在通过此次收购增强其北美生物制药业务，同时约 140 名 MacroGenics 员工将被 Bora 招聘</p>

<p>•MacroGenics to receive $122.5 million upfront payment from Bora upon closing</p>
<div class="lb-trans"><p>•MacroGenics 将在交易完成后从 Bora 获得 1.225 亿美元的预付款</p>
</div><p>•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora</p>
<div class="lb-trans"><p>•交易包括将制造基地、合同开发与制造（CDMO）业务及相关人员转移至 Bora</p>
</div><p>ROCKVILLE, MD, May 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced that they had entered into a definitive agreement in which MacroGenics will sell its good manufacturing practice (GMP) drug substance manufacturing operations to Bora, subject to customary closing conditions.</p>
<div class="lb-trans"><p>马里兰州洛克维尔，2026 年 5 月 11 日（全球新闻通讯社）——MacroGenics, Inc.（纳斯达克：MGNX），一家专注于开发创新抗体治疗癌症的临床阶段生物制药公司，以及 Bora Pharmaceuticals Co., Ltd.（台湾证券交易所：6472；OTCQX：BORAY），一家全球领先的制药制造公司，今天宣布他们已达成一项最终协议，MacroGenics 将把其良好生产规范（GMP）药物原料生产业务出售给 Bora，交易需满足常规的成交条件。</p>
</div><p>“When MacroGenics articulated its strategic priorities last year, we committed to building a more focused company centered on advancing our innovative pipeline and delivering long-term shareholder value. This transaction supports that strategy by providing additional non-dilutive capital to accelerate our pipeline to key value inflection points in 2026 and beyond,” said Eric Risser, President and Chief Executive Officer of MacroGenics. “This transaction will also allow the contract development and manufacturing organization (CDMO) operation to expand under Bora’s ownership, while enabling MacroGenics to maintain access to an expanded array of development and manufacturing capabilities to support our current and future pipeline.”</p>
<div class="lb-trans"><p>“当 MacroGenics 在去年阐明其战略优先事项时，我们承诺建立一个更专注的公司，致力于推进我们的创新管线并为股东创造长期价值。这笔交易通过提供额外的非稀释资本来加速我们的管线，支持我们在 2026 年及以后的关键价值转折点，这与我们的战略相符，” MacroGenics 的总裁兼首席执行官 Eric Risser 表示。“这笔交易还将使合同开发与制造组织（CDMO）业务在 Bora 的所有权下扩展，同时使 MacroGenics 能够继续获得扩展的开发和制造能力，以支持我们当前和未来的管线。”</p>
</div><p>“We are excited to integrate this high-quality Maryland manufacturing site and its talented workforce into our group’s global CDMO effort,” said Bobby Sheng, Chairman of the Bora Group. “We view this acquisition as a key part of our strategy to expand Bora’s North American biologics operation under Bora Biologics. Along with our Drug Product operations in Baltimore, we aim to establish Bora as a partner of choice for end to end clinical and commercial production of biologics drug substance and drug product.”</p>
<div class="lb-trans"><p>“我们很高兴将这个高质量的马里兰制造基地及其优秀的员工整合到我们集团的全球 CDMO 努力中，” Bora 集团董事长 Bobby Sheng 表示。“我们将这次收购视为我们战略的重要组成部分，旨在扩大 Bora 在北美的生物制药业务，隶属于 Bora Biologics。结合我们在巴尔的摩的药物产品业务，我们的目标是将 Bora 建立为生物药物原料和药物产品的临床及商业生产的首选合作伙伴。”</p>
</div><p>Under the terms of the Asset Purchase Agreement, Bora will pay MacroGenics an upfront payment of $122.5 million, before transaction fees and expenses. Upon closing, Bora will assume responsibility for MacroGenics’ manufacturing operations supporting clinical and commercial production. Both the Rockville, Maryland headquarters site, including the FDA-approved facility with total capacity of 11,000 liters, and Frederick, Maryland warehouse will transfer to Bora. In addition, approximately 140 MacroGenics employees are expected to be hired by Bora. The companies will jointly work to ensure a seamless transition and continued service for both MacroGenics and any existing CDMO client. As part of the transaction, MacroGenics will have a supply arrangement with Bora to support process development and drug substance production for its internal pipeline needs. The transaction is expected to close in the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions.</p>
<div class="lb-trans"><p>根据资产购买协议的条款，Bora 将向 MacroGenics 支付 1.225 亿美元的预付款，交易费用和支出除外。交易完成后，Bora 将承担支持临床和商业生产的 MacroGenics 制造业务的责任。位于马里兰州洛克维尔的总部，包括 FDA 批准的总容量为 11,000 升的设施，以及马里兰州弗雷德里克的仓库将转移给 Bora。此外，预计约 140 名 MacroGenics 员工将被 Bora 聘用。两家公司将共同努力确保无缝过渡，并继续为 MacroGenics 及任何现有 CDMO 客户提供服务。作为交易的一部分，MacroGenics 将与 Bora 达成供应协议，以支持其内部管线需求的工艺开发和药物原料生产。交易预计将在 2026 年第三季度完成，需满足或放弃常规成交条件。</p>
</div><p>Moelis &amp; Company LLC served as exclusive financial advisor, and Sidley Austin LLP served as legal counsel to MacroGenics in connection with this transaction.</p>
<div class="lb-trans"><p>Moelis &amp; Company LLC 担任本次交易的独家财务顾问，Sidley Austin LLP 担任 MacroGenics 的法律顾问。</p>
</div><p>Jones Day served as legal counsel to Bora in connection with this transaction.</p>
<div class="lb-trans"><p>Jones Day 担任 Bora 在本次交易中的法律顾问。</p>
</div><p><strong>About MacroGenics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 MacroGenics, Inc.</strong></p>
</div><p>MacroGenics is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. MacroGenics generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see MacroGenics’ website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.</p>
<div class="lb-trans"><p>MacroGenics 是一家专注于开发创新单克隆抗体治疗癌症的生物制药公司。MacroGenics 的产品候选管线主要来自其专有的下一代抗体技术平台，这些平台在广泛的治疗领域中具有适用性。MacroGenics 的技术平台与蛋白质工程专业知识的结合，使公司能够生成有前景的产品候选者，并与全球制药和生物技术公司建立多项战略合作关系。有关更多信息，请访问 MacroGenics 的网站 www.macrogenics.com。MacroGenics 及其标志为 MacroGenics, Inc.的商标或注册商标。</p>
</div><p><strong>About Bora Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>关于 Bora Pharmaceuticals</strong></p>
</div><p>Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, Bora empowers pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, Bora actively broadens R&amp;D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.</p>
<div class="lb-trans"><p>Bora Pharmaceuticals（“Bora” 或 “公司”，6472.TW 和 BORAY.OTCQX）成立于 2007 年，是一家领先的制药服务公司，愿景和目标是 “为全球更好的健康做贡献”。Bora 采用 “双引擎” 模式，整合 CDMO 和商业专业知识，帮助制药和生物技术合作伙伴优化产品开发，加速上市，并扩大供应以满足全球患者需求。同时，Bora 积极拓展研发和销售基础设施，专注于小众和罕见疾病市场，以改善患者的生活质量。</p>
</div><p>By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.</p>
<div class="lb-trans"><p>通过投资人才、基础设施和生物制药扩展，Bora 持续转型运营，实现可持续增长。Bora 致力于使成功 “确定”，在制药和 CDMO 行业树立新标准。</p>
</div><p><strong>Cautionary Note on Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of clinical updates and safety and efficacy data for the Company’s ongoing clinical trials and other statements containing the words “subject to”, &#34;believe&#34;, “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential,” “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy, including our ability to execute on our key strategic priorities for 2025 and 2026, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, lorigerlimab, ZYNYZ, or any other product candidate’s revenue, expenses and costs may not be as expected, risks relating to TZIELD, lorigerlimab, ZYNYZ, or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data updates, including timing and results of efficacy and safety data with respect to product candidates in ongoing clinical trials; our ability to provide manufacturing services to our customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations of expanding ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</p>
<div class="lb-trans"><p>本新闻稿中关于 MacroGenics（“公司”）未来预期、计划和前景的任何声明，包括关于公司战略、未来运营、公司治疗候选药物的临床开发和监管计划、临床更新和公司正在进行的临床试验的安全性和有效性数据发布的预期时间，以及包含 “受制于”、“相信”、“预期”、“计划”、“期待”、“打算”、“估计”、“潜在”、“项目”、“可能”、“将”、“应该”、“会”、“能够”、“可以” 等词语的其他声明，或通过战略讨论，包括我们在 2025 年和 2026 年执行关键战略优先事项的能力，构成根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明。实际结果可能因各种重要因素而与这些前瞻性声明所指示的结果有重大差异，包括：TZIELD、lorigerlimab、ZYNYZ 或任何其他产品候选药物的收入、费用和成本可能未如预期，TZIELD、lorigerlimab、ZYNYZ 或任何其他产品候选药物的市场接受度、竞争、报销和监管行动的风险；未来数据更新，包括关于正在进行的临床试验中产品候选药物的有效性和安全性数据的时间和结果；我们为客户提供制造服务的能力；未来临床试验的启动和招募中固有的不确定性；为资助我们产品候选药物的内部开发而获得融资的可用性；扩展正在进行的临床试验的预期；监管审查过程中的时间和步骤要求的预期；监管批准的预期；未来里程碑付款的预期；竞争产品的影响；我们与战略合作伙伴达成协议的能力以及可能影响公司产品候选药物的可用性或商业潜力的其他事项；由于灾难或其他事件（包括自然灾害、恐怖袭击、内乱和实际或威胁的武装冲突，或公共卫生危机）导致的商业、经济或政治中断；诉讼费用和未能成功辩护诉讼及其他对我们的索赔；以及公司在向证券交易委员会提交的文件中描述的其他风险。此外，本新闻稿中包含的前瞻性声明仅代表公司截至本日期的观点。公司预计后续事件和发展将导致公司观点的变化。然而，尽管公司可能选择在未来某个时点更新这些前瞻性声明，但公司特别声明不承担这样做的任何义务，除非法律要求。这些前瞻性声明不应被视为代表公司在本日期之后的任何日期的观点。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE56ZzFNeU0zTlRrMk9UYzFJekl3TURnNU5UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxNzg1MyM3NTk2OTc1IzIwMDg5NTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjhjYmJkN2ItMDIzNC00N2FjLThlYmMtMTQ0NjE2ZjA0OTc4LTEwMjA1MzAtMjAyNi0wNS0xMS1lbg==/tiny/MacroGenics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YjhjYmJkN2ItMDIzNC00N2FjLThlYmMtMTQ0NjE2ZjA0OTc4LTEwMjA1MzAtMjAyNi0wNS0xMS1lbg==/tiny/MacroGenics-Inc-.png"/></p>
<pre><code>MacroGenics:Jim Karrels, Senior Vice President, CFO1-301-251-5172info@macrogenics.comArgot Partners1-212-600-1902macrogenics@argotpartners.com
</code></pre>
<div class="lb-trans"><pre><code>MacroGenics:Jim Karrels, 高级副总裁，首席财务官 1-301-251-5172info@macrogenics.comArgot Partners1-212-600-1902macrogenics@argotpartners.com
</code></pre>
</div>

MacroGenics 将其 GMP 制造业务出售给 Bora Pharmaceuticals | MGNX 股票新闻